CTR20261620 Sirolimus Xerophthalmia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Turn a newly registered trial into a decision-ready clinical landscape. This report examines CTR20261620 using PatSnap Clinical Trials MCP for protocol design and endpoint evidence, with Drug & Asset MCP and Company & Deal Intelligence MCP used as the companion asset and sponsor enrichment workflow. Explore PatSnap MCP Servers to reproduce the research sequence inside an AI workflow.
MCP evidence snapshot: 24 July 2026. Trial records, recruitment status and projected dates can change after the snapshot and should be rechecked before operational decisions.
Why CTR20261620 is a hot trial to watch
Xerophthalmia is being segmented by mechanism, treatment setting, geography and endpoint architecture. CTR20261620 is notable because it evaluates Sirolimus in a Phase 2 design sponsored by Fuzhou Haoji Pharmaceutical Technology Development Co., Ltd.. The main development question is whether the protocol can translate its rationale into a clinically interpretable and operationally credible readout.
Trial landscape snapshot
| Field | Indexed detail |
|---|---|
| Registration | CTR20261620 |
| Official title | HCKJ-HN01 II期临床试验 |
| Phase / status | Phase 2 / 进行中 （尚未招募） |
| Intervention | Sirolimus |
| Sponsor | Fuzhou Haoji Pharmaceutical Technology Development Co., Ltd. |
| Geography | China |
| Enrollment | [object Object] |
| Primary endpoint | |
| Endpoint time frame | 第12周 |
| Primary completion / readout proxy | Not reported |
Protocol design and endpoint interpretation
The indexed record describes a Phase 2 study of Sirolimus in Xerophthalmia.
Allocation is 随机化, masking is 双盲, and the intervention model is 平行分组. Planned enrollment of [object Object] participants across China shapes statistical precision, execution risk and external validity. Interpretation should account for baseline risk, prior therapy, assessment schedule, missing-data handling and clinical relevance—not only statistical significance.
- Primary endpoint (第12周) — 研究眼角膜荧光素染色（CFS）总分相对基线的变化值。
Readout outlook and evidence gap
The current protocol points to Not reported as the best available readout proxy. Because this is an active or newly posted study, a trial-specific result citation is not included until a normalized clinical-trial-result record becomes available. That gap is itself operationally important: teams should monitor first result indexing, conference abstracts, protocol amendments and changes to the primary-completion date.
Build a living trial monitor: connect to PatSnap MCP Servers and track recruitment, endpoint revisions, projected readouts and new result records without manually reconciling separate databases.
Asset and sponsor context
Drug & Asset MCP profile: Sirolimus is indexed as Non-degrading molecular glue, with target mTOR, mechanism mTOR inhibitors, and global highest development status Approved.
Company & Deal Intelligence MCP profile: Fuzhou Haoji Pharmaceutical Technology Development Co., Ltd. is resolved to a normalized organization record in Fuzhou, China. The organization workflow adds identity, location, portfolio and partnering context where available.
The sponsor profile matters because scientific rationale alone does not determine development value. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.
White space around this program
- Sharper patient selection: prospective biomarker or phenotype definitions that identify who is most likely to benefit.
- Clinically interpretable endpoints: outcomes connecting activity with function, symptoms, survival or treatment burden.
- Comparator relevance: evidence against the most decision-relevant contemporary standard of care.
- Broader external validity: evidence across additional geographies, demographic groups and real-world settings.
- Operational differentiation: a development path that closes the readout gap without sacrificing safety or durability.
What to monitor next
Monitor recruitment, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. A change in endpoint, population or ownership can alter the probability of success before a headline data release.
Bottom line
CTR20261620 provides a focused lens on Xerophthalmia development. Its value will be determined by whether Sirolimus can convert the current Phase 2 design into evidence that is clinically meaningful, operationally credible and differentiated from competing programs.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.
